Results 171 to 180 of about 6,337 (212)
Some of the next articles are maybe not open access.
Annales d'endocrinologie, 2012
The vaptans are non-peptide arginine-vasopressin-receptor antagonists, that are orally and intravenously active. A few vaptans have undergone sufficient clinical development to be on the market. In the EU only tolvaptan is accepted to treat hyponatremia related to SIADH. The place of this new treatment is compared with water restriction, demeclocyclin,
openaire +1 more source
The vaptans are non-peptide arginine-vasopressin-receptor antagonists, that are orally and intravenously active. A few vaptans have undergone sufficient clinical development to be on the market. In the EU only tolvaptan is accepted to treat hyponatremia related to SIADH. The place of this new treatment is compared with water restriction, demeclocyclin,
openaire +1 more source
Wallenberg Syndrome with SIADH
European Neurology, 2004Nobuatsu, Nomoto +4 more
openaire +2 more sources
Medication-Induced SIADH: Distribution and Characterization According to Medication Class
British Journal of Clinical Pharmacology, 2017Talia Diker-Cohen +2 more
exaly

